ScholarIQanswers from OpenAlex & ORCID
Martin H. Voss
ResearcherPublications, citations & collaboration network
Martin H. Voss is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Martin H. Voss have?
ScholarIQindexed works
Martin H. Voss has 573 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Martin H. Voss have?
ScholarIQcitation count
Martin H. Voss has 23,471 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Martin H. Voss?
ScholarIQh-index
Martin H. Voss has an h-index of 57 in OpenAlex.
What is the i10-index of Martin H. Voss?
ScholarIQi10-index
Martin H. Voss has an i10-index of 153 in OpenAlex.
What is the ORCID of Martin H. Voss?
ScholarIQorcid
The ORCID for Martin H. Voss is on the source record.
What is the OpenAlex record for Martin H. Voss?
ScholarIQopenalex
The OpenAlex for Martin H. Voss is on the source record.
What are the most-cited papers on Martin H. Voss?
ScholarIQmost cited works
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Matthew D. Hellmann, Ronglai Shen, Yelena Y. Janjigian, David Barron, Ahmet Zehir, Emmet Jordan, Antonio Omuro, Thomas Kaley, Sviatoslav M. Kendall, Robert J. Motzer, A. Ari Hakimi, Martin H. Voss, Paul Russo, Jonathan E. Rosenberg, Gopa Iyer, Bernard H. Bochner, Dean F. Bajorin, Hikmat Al‐Ahmadie, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Shrujal S. Baxi, Alan L. Ho, Richard J. Wong, David G. Pfister, Jedd D. Wolchok, Christopher A. Barker, Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris
OncoKB: A Precision Oncology Knowledge Base
Debyani Chakravarty, Jianjiong Gao, Sarah Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E. Rudolph, Rona Yaeger, Tara E. Soumerai, Moriah H. Nissan, Matthew T. Chang, Sarat Chandarlapaty, Tiffany A. Traina, Paul K. Paik, Alan L. Ho, Feras Hantash, Andrew Grupe, Shrujal S. Baxi, Margaret K. Callahan, Alexandra Snyder, Ping Chi, Daniel C. Danila, Mrinal M. Gounder, James J. Harding, Matthew D. Hellmann, Gopa Iyer, Yelena Y. Janjigian, Thomas Kaley, Douglas A. Levine, Maeve A. Lowery, Antonio Omuro, Michael A. Postow, Dana E. Rathkopf, Alexander N. Shoushtari, Neerav Shukla, Martin H. Voss, Ederlinda Paraiso, Ahmet Zehir, Michael F. Berger, Barry S. Taylor, Leonard B. Saltz, Gregory J. Riely, Marc Ladanyi, David M. Hyman, José Baselga, Paul Sabbatini, David B. Solit, Nikolaus Schultz
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo, Xuan Wang, Kaitlin M. Woo, Tunç Iyriboz, Darragh Halpenny, Jane Cunningham, Jamie E. Chaft, Neil H. Segal, Margaret K. Callahan, Alexander M. Lesokhin, Jonathan E. Rosenberg, Martin H. Voss, Charles M. Rudin, Hira Rizvi, Xue Hou, Katherine Rodríguez, Melanie Albano, Ruth-Ann Gordon, Charles Leduc, Natasha Rekhtman, Bianca Harris, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Benjamin Y. Kong, Jedd D. Wolchok, Michael A. Postow, Georgina V. Long, Matthew D. Hellmann
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi, Ben Creelan, Francisco Sánchez-Vega, Arun Ahuja, Ai Ni, Jacki B. Novik, Levi Mangarin, Mohsen Abu-Akeel, Cailian Liu, Jennifer L. Sauter, Natasha Rekhtman, Eliza Chang, Margaret K. Callahan, Jamie E. Chaft, Martin H. Voss, Megan Tenet, Xuemei Li, Kelly L. Covello, Andrea Renninger, Patrik Vitazka, William J. Geese, Hossein Borghaei, Charles M. Rudin, Scott Antonia, Charles Swanton, Jeff Hammerbacher, Taha Merghoub, Nicholas McGranahan, Alexandra Snyder, Jedd D. Wolchok
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
Sumanta K. Pal, Laurence Albigès, Piotr Tomczak, Cristina Suárez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi, Friedemann Zengerling, Chan Kim, Takahiro Osawa, Martín Ángel, Suyasha Gupta, Omara Khan, Guillaume Bergthold, Bo Liu, Melania Kalaitzidou, Mahrukh Huseni, Christian Scheffold, Thomas Powles, Toni K. Choueiri